Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Arizona State Retirement System

Arizona State Retirement System boosted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 9.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,648 shares of the company’s stock after purchasing an additional 2,267 shares during the period. Arizona State Retirement System’s holdings in Intellia Therapeutics were worth $574,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in NTLA. Charles Schwab Investment Management Inc. grew its holdings in Intellia Therapeutics by 2.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 700,228 shares of the company’s stock worth $21,350,000 after acquiring an additional 18,987 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Intellia Therapeutics by 5.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,170,829 shares of the company’s stock worth $35,704,000 after acquiring an additional 60,748 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Intellia Therapeutics by 23.3% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 8,204 shares of the company’s stock worth $242,000 after acquiring an additional 1,553 shares in the last quarter. Vanguard Personalized Indexing Management LLC acquired a new position in Intellia Therapeutics during the 4th quarter worth $206,000. Finally, Norges Bank acquired a new position in shares of Intellia Therapeutics in the 4th quarter valued at about $16,348,000. 88.77% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NTLA has been the subject of several research reports. Royal Bank of Canada decreased their price target on shares of Intellia Therapeutics from $60.00 to $54.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Evercore ISI upgraded shares of Intellia Therapeutics to a “strong-buy” rating in a research report on Friday, August 9th. Canaccord Genuity Group reiterated a “buy” rating and issued a $73.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, June 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 24th. Finally, Stifel Nicolaus cut their price objective on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday, September 11th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $61.77.

Intellia Therapeutics Stock Down 2.5 %

Shares of Intellia Therapeutics stock opened at $21.51 on Tuesday. The stock has a market capitalization of $2.18 billion, a P/E ratio of -4.01 and a beta of 1.77. The company has a 50-day simple moving average of $23.38 and a 200 day simple moving average of $24.33. Intellia Therapeutics, Inc. has a 12-month low of $19.21 and a 12-month high of $35.88.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The business had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $19.68 million. The company’s quarterly revenue was down 48.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.40) EPS. On average, equities analysts anticipate that Intellia Therapeutics, Inc. will post -5.19 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.